Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2024
0mins
Source: Newsfilter
DEEp OCEAN Study Launch: Longboard Pharmaceuticals has initiated the DEEp OCEAN Study, a global Phase 3 clinical trial to evaluate the efficacy of its investigational drug bexicaserin for treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in participants aged two years and older.
Community Impact and Access: The trial aims to address significant unmet needs within the DEE community by providing access to innovative medications and clinical trials, thereby promoting equity for underserved patients and their families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
